SWX:SKIN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. More Details


Snowflake Analysis

Exceptional growth potential with mediocre balance sheet.

Share Price & News

How has Cassiopea's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SKIN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: SKIN's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-4.6%

SKIN

3.9%

CH Pharmaceuticals

0.4%

CH Market


1 Year Return

7.3%

SKIN

-5.9%

CH Pharmaceuticals

-0.4%

CH Market

Return vs Industry: SKIN exceeded the Swiss Pharmaceuticals industry which returned -5.9% over the past year.

Return vs Market: SKIN exceeded the Swiss Market which returned -0.4% over the past year.


Shareholder returns

SKINIndustryMarket
7 Day-4.6%3.9%0.4%
30 Day-2.0%3.4%2.8%
90 Day-9.3%4.2%5.8%
1 Year8.0%7.3%-2.7%-5.9%3.1%-0.4%
3 Year23.0%22.2%38.4%18.4%19.8%4.7%
5 Year47.6%46.7%38.6%11.3%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Cassiopea's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cassiopea undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SKIN (CHF44) is trading below our estimate of fair value (CHF882.51)

Significantly Below Fair Value: SKIN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SKIN is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.

PE vs Market: SKIN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SKIN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SKIN is overvalued based on its PB Ratio (19.1x) compared to the CH Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is Cassiopea forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

55.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SKIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: SKIN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SKIN's is expected to become profitable in the next 3 years.

Revenue vs Market: SKIN's revenue (49.8% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: SKIN's revenue (49.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SKIN's Return on Equity is forecast to be very high in 3 years time (60.1%).


Next Steps

Past Performance

How has Cassiopea performed over the past 5 years?

-10.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SKIN is currently unprofitable.

Growing Profit Margin: SKIN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SKIN is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.

Accelerating Growth: Unable to compare SKIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SKIN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.8%).


Return on Equity

High ROE: SKIN has a negative Return on Equity (-49.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cassiopea's financial position?


Financial Position Analysis

Short Term Liabilities: SKIN's short term assets (€11.4M) exceed its short term liabilities (€2.4M).

Long Term Liabilities: SKIN's short term assets (€11.4M) exceed its long term liabilities (€8.0K).


Debt to Equity History and Analysis

Debt Level: SKIN's debt to equity ratio (0.02%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if SKIN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SKIN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SKIN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 15.2% each year


Next Steps

Dividend

What is Cassiopea current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SKIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SKIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SKIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SKIN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SKIN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Diana Harbort (54 yo)

6yrs

Tenure

€482,986

Compensation

Ms. Diana Harbort serves as the Chief Executive Officer of Cassiopea S.p.A. since 2015 and has been its Executive Director since May 2015. Ms. Harbort served as the Head of Corporate Development at Medicis...


CEO Compensation Analysis

Compensation vs Market: Diana's total compensation ($USD583.95K) is below average for companies of similar size in the Swiss market ($USD1.04M).

Compensation vs Earnings: Diana's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Diana Harbort
CEO & Executive Director6yrs€482.99kno data
Pierpaolo Guzzo
CFO & Executive Director5.75yrs€42.24kno data
Marco Pasero
Chief Operating Officer6yrsno datano data
Luigi Moro
Chief Scientific Officer6yrsno datano data
Sheetal Sahel
Vice President of Marketing2yrsno datano data
Dave Wood
Vice President of Sales2yrsno datano data
Alessandro Mazzetti
Chief Medical Officer4yrsno datano data
Martina Cartwright
Senior Director of Medical Affairsno datano datano data

5.0yrs

Average Tenure

54yo

Average Age

Experienced Management: SKIN's management team is seasoned and experienced (5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Diana Harbort
CEO & Executive Director6yrs€482.99kno data
Pierpaolo Guzzo
CFO & Executive Director5.75yrs€42.24kno data
James Leyden
Member of Scientific Advisory Boardno datano datano data
Ken Washenik
Member of Scientific Advisory Boardno datano datano data
Jan de Vries
Non-Executive Independent Chairman6yrs€38.73k0.60%
€ 2.6m
Diane Thiboutot
Member of Scientific Advisory Boardno datano datano data
Øyvind Bjordal
Non-Executive Independent Director5.67yrs€42.24kno data
Andrea Zaenglein
Member of Scientific Advisory Boardno datano datano data
Maurizio Baldassarini
Independent & Non Executive Director2.75yrs€42.24kno data

5.7yrs

Average Tenure

55.5yo

Average Age

Experienced Board: SKIN's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Cassiopea S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cassiopea S.p.A.
  • Ticker: SKIN
  • Exchange: SWX
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF440.000m
  • Shares outstanding: 10.00m
  • Website: https://www.cassiopea.com

Number of Employees


Location

  • Cassiopea S.p.A.
  • Via Cristoforo Colombo, 1
  • Lainate
  • Milan
  • 20020
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SKINSWX (SIX Swiss Exchange)YesRegistered SharesCHCHFJul 2015
0R8YLSE (London Stock Exchange)YesRegistered SharesGBCHFJul 2015
CSPDB (Deutsche Boerse AG)YesRegistered SharesDEEURJul 2015
SKINZBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBCHFJul 2015
CPPS.FOTCPK (Pink Sheets LLC)YesRegistered SharesUSUSDJul 2015

Biography

Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has complete...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:12
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.